Use of Platelet-enriched Plasma During Auricular Reconstruction

NCT ID: NCT03215979

Last Updated: 2018-02-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-29

Study Completion Date

2018-12-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study investigators are trying to determine the benefits of using platelet enriched plasma during the second stage of auricular reconstruction. The intervention will be blinded to the surgeon and the surgical team. The main outcome will be the evaluation of the integration rate of the skin full thickness graft used to coat the auricular frame.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ear Cartilage Platelets Microtia-Anotia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PEP-Arm

In this arm, surgeon will be applying platelet enriched plasma(PEP) (5 ml) during the second stage procedure of auricular reconstruction. PEP will be infected in the temporal fascia used to cover the cartilage frame.

Group Type EXPERIMENTAL

Platelet enriched plasma administration

Intervention Type PROCEDURE

It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft

Placebo-Arm

This arm will be used as control. The surgeon will inject 0.9% saline solution (5ml) in a blinded basis.

Group Type PLACEBO_COMPARATOR

Placebo Arm

Intervention Type PROCEDURE

5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Platelet enriched plasma administration

It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft

Intervention Type PROCEDURE

Placebo Arm

5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Microtia Tanzer II-A
* patients aged 8-12 years
* Haemoglobin \> 10 gr/dL
* History of first stage of auricular reconstruction

Exclusion Criteria

* associated endocrinopathies
* desnutrition (\<2.5 gr/ dL)
Minimum Eligible Age

8 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital General Dr. Manuel Gea González

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jorge Raúl Carrillo Córdova

Medical Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital General "Dr. Manuel Gea González"

Mexico City, , Mexico

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jorge Raúl Carrillo-Córdova, M.D

Role: primary

01 55 4000 3000 ext. 1323

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

05-20-2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Amnion Wound Covering for Enhanced Wound Healing
NCT03754218 COMPLETED EARLY_PHASE1